SALBUTAMOL ATTENUATES THE ARRHYTHMOGENIC EFFECT OF AMINOPHYLLINE IN CARDIAC ORGANOIDS EXPERIMENTAL MODEL
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F24%3A00137446" target="_blank" >RIV/00216224:14110/24:00137446 - isvavai.cz</a>
Result on the web
<a href="https://www.cksonline.cz/czech-cardiovascular-research-and-innovation-day-2024/sjezd.php?p=read_abstrakt_program&idabstrakta=70" target="_blank" >https://www.cksonline.cz/czech-cardiovascular-research-and-innovation-day-2024/sjezd.php?p=read_abstrakt_program&idabstrakta=70</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
SALBUTAMOL ATTENUATES THE ARRHYTHMOGENIC EFFECT OF AMINOPHYLLINE IN CARDIAC ORGANOIDS EXPERIMENTAL MODEL
Original language description
Background: The combination of aminophylline and salbutamol is used in the treatment of obstructive lung diseases. Side effects (including arrhythmias) of the individual bronchodilator drugs were described, those of combined treatment are almost unknown. We aimed to study the arrhythmogenic potential of combined aminophylline and salbutamol in vitro. Methods: We used the established model of atomic force microscopy (AFM) coupled with cardiac organoids from human pluripotent stem cells (hPSC-CMs). We focused on the chronotropic, inotropic, and arrhythmogenic effects of Salbutamol and Aminophylline alone and combined. Results: Salbutamol and Aminophylline had a synergistic chronotropic and inotropic effects compared to the effects of their separate application. Salbutamol reduced the arrhythmogenic effect of aminophylline, most likely mediated by endothelial nitric oxide synthase activated by beta-2 adrenergic receptors. Findings were replicated and confirmed using hPSC-CM derived from 2 cell lines (CCTL14 and CCTL12). Conclusions: Data suggest that salbutamol as an add-on therapy may not only deliver a bronchodilator effect but also increase the cardiovascular safety of aminophylline, as salbutamol reduces its arrhythmogenic potential. Acknowledgement CarDia (EXCELES, No. LX22NPO5104) EU Next Generation and by the EC Horizon Europe MUQUABIS GA no. 101070546. and MUNI/A/1624/2023 MEYS CR
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů